Trega Biosciences, Inc.

Lion Bioscience Ag

Houghten Pharmaceuticals, Inc.

Other

Lion Bioscience Science Ag

Beverly E Girten

Ronald R Tuttle

Richard Allen Houghten

Mark J Suto

Costas C Loullis

Amaresh Basu

Sandra R Slivka

John S Kiely

Timothy Gahman

Michael C Griffith

Curtis C Hecht

Paul Omholt

Yazhong Pei

Hengyuan Lang

Kevin Ross Holme

Patricia A Weber

Colette Dooley

Karen J Watson-Straughan

Patrick Fagan

Douglas L Hitchin

Ali Andalibi

Kevin C Dines

Timothy C Gahman

Methods for treating erectile dysfunction using tetrahydroisoquinoline aromatic amines that function as melanocortin receptor ligands.

Treatment of erectile dysfunction using isoquinoline compound melanocortin receptor ligands

Methods for treating sexual dysfunction, such as erectile dysfunction or sexual arousal disorder, with a compound having the generic formula X &mdash;X -(D)Phe-Arg-(D)Trp-X . A particularly useful compound is HP-228, which has the formula Ac-Nle-Gln-His-(D)Phe-Arg-(D)Trp-Gly-NH . The invention also provides methods for selecting melanocortin receptor-3 ligands by determining whether a compound modulates the activity of MC-3 as an agonist or antagonist. These methods can be used to screen compound libraries for ligands to treat MC-3-associated conditions. Such conditions include sexual dysfunction, including erectile dysfunction and sexual arousal disorder.

Melanocortin receptor-3 ligands to treat sexual dysfunction

The invention provides ligands for melanocortin receptors. For example, the invention provides the melanocortin receptor peptide ligand Ac-Nlc-Gln-His-(p(I)-D-Phe)-Arg-(D-Trp)-Cly-NH , (SEQ ID NO: 1), where the iodo group is unlabeled or radioactively labeled. The invention additionally provides methods of assaying for melanocortin receptors in a cell or tissue such as brain. The invention also relates to pharmaceutical compositions comprising a pharmaceutically acceptable carrier and a melanocortin receptor ligand and to methods of administering the pharmaceutical composition to a subject. The invention further provides tetrapeptide ligands for melanocortin receptors and methods of altering melanocortin receptor activity.

Melanocortin receptor ligands and methods of using same

HP-3228 and related peptides to treat sexual dysfunction

The present invention provides novel cytokine restraining agents, which limit or control the biological activity of cytokines. The invention also provides pharmaceutical compositions comprising a cytokine restraining peptide and methods of administering the pharmaceutical composition to a subject. The invention further provides methods for using the novel peptides to restrain cytokine activity in a subject.

Cytokine restraining agents

The invention relates to melanocortin receptor ligands and methods of using the ligands to alter or regulate the activity of a melanocortin receptor. The invention further relates to tetrahydroisoquinoline aromatic amines that function as melanocortin receptor ligands and as agents for controlling cytokine-regulated physiologic processes and pathologies, and combinatorial libraries thereof.

Isoquinoline compound melanocortin receptor ligands and methods of using

The present invention provides methods for reducing the severity of GI damage in an individual by administering a cytokine regulatory agent to an individual that is susceptible to developing such damage.

Method for reducing the severity of gastro-intestinal damage

The present invention relates to the use of cytokine restraining agents to treat inflammatory bowel disease.

Use of cytokine restraining agents to treat inflammatory bowel disease

The present invention relates to novel peptides that are potent cytokine restraining agents. In addition, the present invention relates to pharmaceutical compositions comprising a pharmaceutically acceptable carrier and a cytokine restraining agent. Administration of such a cytokine restraining agent to a subject restrains, but does not necessarily suppress, cytokine activity completely. Thus, the present invention provides a method of restraining pathologically elevated cytokine activity in a subject. The invention also provides methods of treating disuse deconditioning and diseases mediated by nitric oxide and cytokines, such as diabetes and glomerulonephritis, a method of organ protection, a method of organ protection, and a method of reducing the negative side effects of cancer chemotherapy, such as nephrotoxicity.

Cytokine restraining agents and methods of use in pathologies and

The present invention relates to the use of a cytokine regulatory agent to reduce the severity of rheumatoid arthritis.

Use of a cytokine regulatory agent to treat rheumatoid arthritis

The present invention relates to novel peptides that are potent cytokine regulatory agents. In addition, the present invention relates to pharmaceutical compositions comprising a pharmaceutically acceptable carrier and a cytokine regulatory agent. Administration of such a cytokine regulatory agent to a subject can enhance or restrain cytokine activity. Thus, the present invention provides a method of regulating cytokine activity in a subject having a condition characterized by aberrant or altered cytokine activity. The invention also provides methods of treating such conditions, including, for example, disuse deconditioning, diseases mediated by nitric oxide and cytokines, adverse drug reactions, obesity, septic shock, and adverse side effects due to cancer chemotherapy or occurring as in response to organ transplantation.

Cytokine regulatory agents and methods of use in pathologies and

The present invention provides a method of reducing a wasting condition, which can occur due to a pathology or to a particular physiologic or metabolic state in a subject, by administering to the subject a substituted 1,3-benzodioxole.

Growing community of inventors

San Diego, CA, United States of America

Beverly E Girten